Alteration in methylation level at 11β-hydroxysteroid dehydrogenase type 2 gene promoter in infants born to preeclamptic women

详细信息    查看全文

• 作者：Wensheng Hu ; Xiaoling Weng ; Minyue Dong ; Yun Liu ; Wenjuan Li ; Hefeng Huang
• 关键词：Preeclampsia ; Offspring ; DNA methylation ; Promoter ; HSD11B2 ; Metabolic diseases
• 刊名：BMC Genetics
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：15
• 期：1
• 全文大小：315 KB
• 参考文献：1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. / Am J Obstet Gynecol 2000, 183:S1–S22.
  2. Rich-Edwards, JW, Grizzard, TA (2005) Psychosocial stress and neuroendocrine mechanisms in preterm delivery. Am J Obstet Gynecol 192: pp. S30-S35 CrossRef
  3. Curhan, GC, Chertow, GM, Willett, WC, Spiegelman, D, Colditz, GA, Colditz, GA, Manson, JE, Speizer, FE, Stampfer, MJ (1996) Birth weight and adult hypertension and obesity in women. Circulation 94: pp. 1310-1315 CrossRef
  4. Barker, DJ, Hales, CN, Fall, CH, Osmond, C, Phipps, K, Clark, PM (1993) Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 36: pp. 62-67 CrossRef
  5. Serman, L, Vlahovic, M, Sijan, M, Bulic-Jakus, F, Serman, A, Sincic, N, Matijevic, R, Juric-Lekic, G, Katusic, A (2007) The impact of 5-azacytidine on placental weight, glycoprotein pattern and proliferating cell nuclear antigen expression in rat placenta. Placenta 28: pp. 803-811 CrossRef
  6. He J, Zhang A, Fang M, Fang R, Ge J, Jiang Y, Zhang H, Han C, Ye X, Yu D, Huang H, Liu Y, Dong M: Methylation levels at IGF2 and GNAS DMRs in infants born to preeclamptic pregnancies. / BMC Genomics 2013, 14:472.
  ACOG practice bulletin. Management of infertility caused by ovulatory dysfunction. Number 34, February 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77: pp. 177-188
  7. Schoof, E, Girstl, M, Frobenius, W, Kirschbaum, M, Dorr, HG, Rascher, W, Dotsch, J (2001) Decreased gene expression of 11beta-hydroxysteroid dehydrogenase type 2 and 15-hydroxyprostaglandin dehydrogenase in human placenta of patients with preeclampsia. J Clin Endocrinol Metab 86: pp. 1313-1317
  8. He, P, Chen, Z, Sun, Q, Li, Y, Gu, H, Ni, X (2014) Reduced expression of 11beta-hydroxysteroid dehydrogenase type 2 in preeclamptic placentas is associated with decreased PPARgamma but increased PPARalpha expression. Endocrinology 155: pp. 299-309 CrossRef
  9. Hardy, DB, Yang, K (2002) The expression of 11 beta-hydroxysteroid dehydrogenase type 2 is induced during trophoblast differentiation: effects of hypoxia. J Clin Endocrinol Metab 87: pp. 3696-3701
  10. Alfaidy, N, Gupta, S, DeMarco, C, Caniggia, I, Challis, JR (2002) Oxygen regulation of placental 11 b-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J Clin Endocrinol 87: pp. 4797-4805 CrossRef
  11. Benediktsson, R, Calder, AA, Edwards, CR, Seckl, JR (1997) Placental 11b-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 46: pp. 161-166 CrossRef
  12. Goland, RS, Jozak, S, Warren, WB, Conwell, IM, Stark, RI, Tropper, PJ (1993) Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses. J Clin Endocrinol Metab 77: pp. 1174-1179
  13. Goland, RS, Tropper, PJ, Warren, WB, Stark, RI, Jozak, SM, Conwell, IM (1995) Concentrations of corticotrophin-releasing hormone in the umbilical-cord blood of pregnancies complicated by pre-eclampsia. Reprod Fertil Dev 7: pp. 1227-1230 CrossRef
  14. Seckl, JR, Meaney, MJ (2004) Glucocorticoid programming. Ann N Y Acad Sci 1032: pp. 63-84 CrossRef
  15. Meaney, MJ, Szyf, M, Seckl, JR (2007) Epigenetic mechanisms of perinatal programming of hypothalamic-pituitary-adrenal function and health. Trends Mol Med 13: pp. 269-277 CrossRef
  16. Jaquiery, AL, Oliver, MH, Bloomfield, FH, Connor, KL, Challis, JR, Harding, JE (2006) Fetal exposure to excess gluc
• 刊物主题：Life Sciences, general; Animal Genetics and Genomics; Microbial Genetics and Genomics; Plant Genetics & Genomics; Genetics and Population Dynamics;
• 出版者：BioMed Central
• ISSN：1471-2156

文摘

Background Preeclampsia reduces placental expression and activity of 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2), leading to an increase in fetal glucocordicoids. The latter has been proposed to be associated with low birth weight and high risk of metabolic diseases in later life of the offspring. This investigation aims to delineate the alteration in methylation levels at CpG sites of HSD11B2 promoter. Results Methylation levels of HSD9-2, HSD9-3, HSD23-2 and HSD23-3 and the mean methylation level were significantly lower in preeclampsia than in normal pregnancy (P--.002, 0.031, 0.047 and 0.001, respectively and P--.001 in mean). The mean methylation level was significantly correlated with preeclampsia after the adjustment of birth weight, maternal age, gestational age at delivery and fetal gender (r--.325, P--.001). Conclusions Preeclampsia reduced methylation level at fetal HSD11B2 promoter. A positive correlation existed between HSD11B2 promoter methylation and preeclampsia. Our findings suggest that the methyaltion status of HSD11B2 promoter is a potentially accessible biomarker for preeclampsia. However, further studies are required to address the mechanisms of thehypomethylation at HSD11B2 promoter and the significance of the hypomethylation in the development of metabolic diseases of the fetals born to preeclamptic women.